Brind.

FDA refused Summit Therapeutics' drug, and the stock's market performance was compared to Nasdaq.

1 report, 1 independent Updated 16:30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FDA refused Summit Therapeutics' drug, and the stock's market performance was compared to Nasdaq.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped